TKPHF OTC
Credit Risk of going bust: lower than 78% of companies Debt: 32.5% of company value Bonds: none of note held by US funds details ▾
Total debt $31.37B against a stock market value of $65.02B.
Distance to default 9.16 (Merton model): prices to 2026-10-23, balance sheet 2026-06-30, debt counted $17.34B (short-term plus half of long-term), stock volatility 21.6%; Altman Z'' 1.53. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Tokyo, OS 103-8668
JP
Takeda Pharmaceutical Company Limited, an established global biopharmaceutical entity founded in 1781 and based in Tokyo, Japan, is comprehensively involved in the entire process of bringing new medicines to market. This includes the research, development, production, commercialization, and external licensing of its pharmaceutical products across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and other parts of Asia. The company concentrates its therapeutic endeavors on key medical areas such as digestive health (gastroenterology), rare disorders, treatments derived from blood plasma, cancer care (oncology), and neurological conditions. Its extensive portfolio features numerous well-known brands, including Entyvio, Takhzyro, Velcade, Livtencity, and Dexilant, among others. Takeda actively cultivates a wide-ranging network of strategic partnerships and collaborations. This includes out-licensing agreements, for example with Neurocrine Biosciences, Inc.; in-licensing deals and research collaborations with organizations like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and joint research efforts with companies such as Crescendo Biologics and Skyhawk Therapeutics. Furthermore, Takeda maintains strategic alliances with entities like Evotec SE and KSQ Therapeutics, underscoring its commitment to external innovation.